BioSpace News Archive

PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, and Clinical Ink, a global clinical technology company, have jointly developed a systemic lupus erythematosus (SLE) assessment review process to simplify operationalizing clinical trials for this chronic autoimmune disease.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), the medical technology company that pioneered the Tablo Hemodialysis System, a first-of-its-kind device to reduce the cost and complexity of dialysis, is strengthening its consumer focus with the appointment of Andrea Saia to its board of directors.

ROSINBOMB (OTC:ROSN), industry leading developer and manufacturer of the highly acclaimed ROSINBOMB line of solventless extraction presses and Industry Icon Tommy Chong, announced today the launch of a limited edition series of custom art skinned Rosinbomb Rocket consumer extraction presses.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Judith A. Dunn, Ph.D. has been appointed President of Research and Development.

It is the intention of the parties that the resulting issuer from the Transaction (the “Resulting Issuer”) will carry on the current business of Psygen.

To support quality improvement (QI) projects in colorectal cancer, the Association of Community Cancer Centers (ACCC) has joined with Pfizer Global Medical Grants to issue a Request for Proposals (RFP) with the intent of funding QI initiatives that focus on the integration of biomarker testing into the treatment planning for patients with metastatic colorectal cancer (mCRC).

Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer, today announced that it had secured $80 million in Series B Financing.

Each year the National Kidney Foundation (NKF) considers the work of hundreds of specialists in the field of nephrology and selects among them those who most exemplify the relentless efforts of NKF

In a press conference today, EirGenix, Inc. (6589.TT) announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint. EG12014 has shown equivalent efficacy to Herceptin® in regards to its clinical response

At today’s virtual combined Annual General Shareholders’ Meeting of Sartorius Stedim Biotech S.A., shareholders passed the resolution to pay a dividend of 0.68 euros per share for fiscal 2020